Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Cantor Fitzgerald adjusted its outlook on Amgen shares (NASDAQ:AMGN), reducing the price target from the previous $405.00 to $340.00. Despite the lowered price target, the firm maintained its ...

Experts say the kuranui, otherwise known as moa, played a vital part in sustaining rākau Māori, crucial to the wellbeing of the taiao and the Māori language. The kuranui, otherwise known as moa ...

A SEVENTEEN pop-up store has officiall opened at the Mall of Asia on Wednesday. But it's not just any SEVENTEEN pop-up store, it's an “Artist-Made Collection by SEVENTEEN” pop-up store. Located at the ...

Read on for details on that and other highlights from the conference: Amgen’s market value rose and fell by billions of dollars last year on the promise of an obesity drug called MariTide.

However, the spotlight is on Amgen's obesity drug candidate, MariTide. This product is generating significant buzz in the investment community due to its potential to become a major revenue driver.

However, the spotlight is on Amgen's obesity drug candidate, MariTide. This product is generating significant buzz in the investment community due to its potential to become a major revenue driver.

Shares of Amgen (Nasdaq: AMGN) started crashing in early November and didn’t improve when the company released data from a phase 2 clinical trial for its weight-loss candidate MariTide.

Its pipeline progress, especially its obesity drug MariTide, positions Amgen, Inc. (NASDAQ:AMGN) for long-term growth. The company’s move towards rare diseases exhibited strong momentum in late ...

Helicore’s lead drug, dubbed HCR-188, blocks GIP ligands in digestive cells, setting it apart from drugs like Eli Lilly’s Zepbound and Amgen’s MariTide, which take aim at GIP receptors found ...